logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11154572 B1

PDFFull Text
Date of Patent:
Oct. 26, 2021

Filed:

Jun. 06, 2016

Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type

Applicant:

Board of Regents, the University of Texas System, Austin, TX (US);

Inventors:

Katy Rezvani, Houston, TX (US);

Elizabeth Shpall, Houston, TX (US);

Enli Liu, Houston, TX (US);

Assignee:

Board of Regents, The University of Texas System, Austin, TX (US);

Attorney:

Norton Rose Fulbright US LLP

Primary Examiner:

G R Ewoldt

Assistant Examiner:

Marianne DiBrino

Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61P 35/02 (2006.01); A61K 31/4525 (2006.01); A61K 39/00 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 14/705 (2006.01); C07K 14/47 (2006.01); A61P 37/06 (2006.01); A61K 31/675 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61P 35/02 (2018.01); A61P 37/06 (2018.01); C07K 14/4748 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 16/28 (2013.01); A61K 31/4525 (2013.01); A61K 31/675 (2013.01); A61K 2300/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01);
Abstract

The present invention concerns methods of treating a disease such as leukemia in a subject by administering natural killer (NK) cells. In particular aspects, HLA-C1-licensed KIR2DL2/3 and KIR2DS2 NK cells are administered to a subject with an HLA-C genotype either homozygous or heterozygous for the C1 allele, or HLA-C2 licensed cells are administered to a subject with an HLA-C genotype homozygous for the C2 allele. In further aspects, the NK cells are genetically modified to express a chimeric antigen receptor and interleukin 15.

Find Patent Forward Citations

Rezvani, Katy. (2021). Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type (U.S. Patent No. 11154572). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11154572

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…